17,352,646 Shares in Cogent Biosciences, Inc. $COGT Purchased by BlackRock Inc.

Key Points

• BlackRock acquired 17.35 million Cogent Biosciences shares during the second quarter, worth approximately $671.5 million and representing a 10.16% stake.
• Other major institutions also increased their positions, including Vanguard, Deerfield Management, RTW Investments, State Street, and Janus Henderson, indicating strong institutional interest in COGT.
• Analysts maintain a generally bullish outlook, with a consensus “Moderate Buy” rating and an average price target of $49.40, although 2026 earnings-loss estimates were revised lower.

BlackRock Inc. acquired a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 17,352,646 shares of the technology company's stock, valued at approximately $671,547,000. BlackRock Inc. owned 10.16% of Cogent Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of COGT. Vanguard Group Inc. increased its position in shares of Cogent Biosciences by 48.4% in the 4th quarter. Vanguard Group Inc. now owns 11,514,326 shares of the technology company's stock valued at $408,989,000 after purchasing an additional 3,756,664 shares during the last quarter. Deerfield Management Company L.P. lifted its holdings in shares of Cogent Biosciences by 242.9% in the 3rd quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company's stock valued at $130,003,000 after purchasing an additional 6,412,903 shares during the last quarter. RTW Investments LP boosted its holdings in shares of Cogent Biosciences by 119.0% in the fourth quarter. RTW Investments LP now owns 7,592,241 shares of the technology company's stock valued at $269,676,000 after acquiring an additional 4,124,755 shares during the period. State Street Corp grew its position in Cogent Biosciences by 3.5% during the 4th quarter. State Street Corp now owns 4,940,300 shares of the technology company's stock worth $175,479,000 after purchasing an additional 164,881 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in shares of Cogent Biosciences by 42.8% during the fourth quarter. Janus Henderson Group PLC now owns 4,537,408 shares of the technology company's stock worth $161,115,000 after buying an additional 1,359,365 shares during the last quarter.

Key Cogent Biosciences News

Here are the key news stories impacting Cogent Biosciences this week:

• Positive Sentiment: HC Wainwright maintained its “Buy” rating and $55 price objective for COGT, signaling confidence in Cogent Biosciences’ longer-term growth prospects. HC Wainwright analyst coverage
• Positive Sentiment: The analyst expects losses to narrow significantly in 2027, forecasting quarterly EPS of $(0.50), $(0.38), $(0.26), and $(0.15), resulting in a full-year loss of $(1.28). The improving trajectory may support the stock’s valuation if Cogent’s pipeline advances as expected. Cogent Biosciences 2027 earnings estimates
• Neutral Sentiment: HC Wainwright initiated its 2027 estimates, including a $(1.28) full-year EPS forecast. These projections provide new expectations for investors but do not represent a change to the company’s operating results. Cogent Biosciences analyst estimates
• Negative Sentiment: HC Wainwright reduced its 2026 EPS forecasts, lowering Q3 estimates to $(0.59) from $(0.56), Q4 estimates to $(0.62) from $(0.57), and full-year estimates to $(2.37) from $(2.21). The revisions indicate higher expected losses in the near term and could limit upside despite the bullish rating. Cogent Biosciences 2026 earnings estimate revisions

Analyst Upgrades and Downgrades

COGT has been the topic of a number of analyst reports. Wedbush reiterated an "outperform" rating and issued a $55.00 price objective on shares of Cogent Biosciences in a research report on Friday, May 29th. Piper Sandler raised their target price on Cogent Biosciences from $52.00 to $55.00 and gave the company an "overweight" rating in a report on Monday, August 17th. Guggenheim raised their price objective on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. HC Wainwright boosted their target price on Cogent Biosciences to $55.00 and gave the stock a "buy" rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Cogent Biosciences Price Performance

Shares of NASDAQ COGT opened at $36.73 on Monday. The firm has a fifty day moving average of $38.49 and a 200-day moving average of $36.62. Cogent Biosciences, Inc. has a 52-week low of $11.60 and a 52-week high of $43.73. The company has a quick ratio of 13.57, a current ratio of 13.57 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $6.37 billion, a PE ratio of -17.00 and a beta of 0.38.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.03. On average, analysts anticipate that Cogent Biosciences, Inc. will post -2.24 EPS for the current year.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source